A Study of REC-1245 in Participants With Unresectable, Locally Advanced, or Metastatic Cancer

Launched by RECURSION PHARMACEUTICALS INC. · Nov 5, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a new medication called REC-1245 for patients with certain types of cancer that cannot be removed by surgery or have spread to other parts of the body. Specifically, the trial is looking at how safe and effective this medication is when taken orally once a day. The goal is to learn more about how the drug works in the body and to see if it can help patients whose cancer has either come back or is resistant to standard treatments.

To be eligible for this study, participants must be 18 years or older and have a confirmed diagnosis of specific advanced solid tumors or certain types of lymphomas that have either progressed or did not respond to previous treatments. They should also be able to perform daily activities with minimal assistance. Throughout the trial, participants will receive the medication and will be monitored for any side effects and how well the drug works. It’s important to note that this study is currently recruiting participants and welcomes individuals of all genders.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 18 years or older Have histologically-confirmed unresectable, locally advanced, or metastatic select solid tumors or select relapsed / refractory lymphoma Have experienced progressive disease, relapsed disease, or be intolerant to at least one established standard systemic anti-cancer treatment for a given tumor type, or have been considered ineligible for standard therapy.
• • ECOG performance status ≤ 1 Measurable disease at baseline per RECIST 1.1 / Lugano criteria and documented by computed CT and / or MRI
• Exclusion Criteria:
• • Received treatment with another RBM39 degrader Clinically significant gastrointestinal (GI) or GI malabsorption